Thermo Fisher Scientific BMPR1A Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

2 µg/mL

View 6 publications 6 publications

Immunohistochemistry (IHC)

-

View 2 publications 2 publications

Immunocytochemistry (ICC/IF)

2 µg/mL

View 2 publications 2 publications

Immunoprecipitation (IP)

Assay-dependent

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse, Rat

Published species

Human, Mouse

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic peptide derived from an internal region of the human BMPR-1A (bone morphogenetic protein receptor type 1A, Serine/threonine protein kinase receptor R5 (SKR5), activin receptor-like kinase-3 (ALK-3)), which differs from mouse and rat BMPR-1A by one nonconservative amino acid replacement.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.25 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.4

Contains

0.1% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2533377

Target Information

BMPR1A is a Type I member of the TGF beta receptor superfamily of transmembrane ser/thr kinases which phosphorylates intracellular SMADs in response to bone morphogenic proteins. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.